Williams J C, DeRosa A, Nakamura Y, Loyacano A F
Department of Veterinary Science, LSU Agricultural Center, Baton Rouge 70803-6002, USA.
Vet Parasitol. 1997 Dec 15;73(1-2):73-82. doi: 10.1016/s0304-4017(97)00066-6.
An experiment was conducted to evaluate the current efficacy of albendazole (ABZ), oxfendazole (OXF) and fenbendazole (FBZ) compared with ivermectin pour-on (IVM-PO) against inhibited early fourth-stage larvae (IEL4) of Ostertagia ostertagi, other gastrointestinal nematodes and lungworm of cattle during spring in Louisiana. Twenty-five crossbred beef heifer calves of 235 kg average weight and 10-12 months of age were acquired in late winter and grazed for 9 weeks on pasture contaminated with O. ostertagi and other nematodes until May 15. The cattle were weighed and randomly allotted into 5 groups of 5 calves on May 16 (day 0) and treatments were as follows: group 1, nontreated controls (CONT); group 2, IVM-PO on mid-backline at 500 micrograms/kg; group 3, ABZ suspension (oral) at 10 mg/kg; group 4, OXF suspension (oral) at 4.5 mg/kg; group 5, FBZ suspension (oral) at 5 mg/kg. After treatment and confinement in separate pens for each group, approximately equal numbers of cattle from each group were necropsied daily between days 29-31. Mean numbers of O. ostertagi developmental stages present in CONT were: adult, 5234; developing (DL4), 3130; IEL4, 44,077. The mean percentage of IEL4 was 84.1. Cooperia spp. were the second most prevalent in CONT (20,307) and smaller numbers of abomasal and intestinal species and Dictyocaulus viviparus were present in nearly all CONT. Percent reductions for the four compounds against O. ostertagi adult, DL4 and IEL4, respectively, were IVM-PO: 99.7, 98.3, 98.1; ABZ: 74.1, 76.5, 75.3; OXF: 78.5, 42.1, 32.0; FBZ: 63.6, 17.7, 39.7. Efficacy of IVM-PO was greater (P < 0.05) against all O. ostertagi stages than the benzimidazole (BZ) drugs, except for ABZ (DL4). There were no significant differences in group means (except for C. punctata adult males, P < 0.05 lower for IVM-PO) or wide variation in reduction percentages for other abomasal and intestinal species and D. viviparus between IVM-PO and BZ drugs. The low efficacy of all three BZ drugs for O. ostertagi, but especially for OXF and FBZ, under conditions of this experiment, were suggestive of drug tolerance to dosages employed or resistance. However, problems of drug availability/concentration in the abomasum, and the factor of IEL4 and DL4 replacing adult worms after treatment cannot be excluded. Efficacy of the BZ drugs against all other species were essentially similar to that of IVM-PO.
开展了一项实验,以评估阿苯达唑(ABZ)、奥芬达唑(OXF)和芬苯达唑(FBZ)与伊维菌素浇泼剂(IVM-PO)相比,在路易斯安那州春季对牛奥斯特他线虫抑制性第四期幼虫(IEL4)、其他胃肠道线虫和肺线虫的当前疗效。25头平均体重235千克、年龄10 - 12个月的杂交肉用小母牛犊于冬末购得,并在感染了奥斯特他线虫和其他线虫的牧场上放牧9周,直至5月15日。5月16日(第0天)对牛进行称重,并随机分为5组,每组5头犊牛,处理方式如下:第1组,未处理对照(CONT);第2组,在中背部按500微克/千克剂量浇泼IVM-PO;第3组,口服10毫克/千克ABZ混悬液;第4组,口服4.5毫克/千克OXF混悬液;第5组,口服5毫克/千克FBZ混悬液。在对每组进行处理并分别圈养在单独的围栏后,在第29 - 31天期间每天对每组大致相等数量的牛进行剖检。CONT组中奥斯特他线虫发育阶段的平均数量为:成虫,5234条;发育中(DL4),3130条;IEL4,44,077条。IEL4的平均百分比为84.1%。库珀属线虫在CONT组中是第二常见的(20,307条),几乎所有CONT组中都存在数量较少的皱胃和肠道线虫种类以及胎生网尾线虫。四种化合物对奥斯特他线虫成虫、DL4和IEL4的减少百分比分别为:IVM-PO:99.7%、98.3%、98.1%;ABZ:74.1%、76.5%、75.3%;OXF:78.5%、42.1%、32.0%;FBZ:63.6%、17.7%、39.7%。除ABZ(DL4)外,IVM-PO对奥斯特他线虫所有阶段的疗效均高于苯并咪唑(BZ)类药物(P < 0.05)。IVM-PO与BZ类药物在其他皱胃和肠道线虫种类以及胎生网尾线虫的组均值上无显著差异(点状库珀线虫成年雄性除外,IVM-PO组较低,P < 0.05),减少百分比的变化也不大。在本实验条件下,所有三种BZ类药物对奥斯特他线虫的疗效较低,尤其是对OXF和FBZ,这表明可能对所用剂量产生了药物耐受性或耐药性。然而,不能排除皱胃中药物可用性/浓度问题以及处理后IEL4和DL4取代成虫的因素。BZ类药物对所有其他线虫种类的疗效与IVM-PO基本相似。